Wedbush Expects Higher Earnings for BioCryst Pharmaceuticals

Key Points

• Wedbush analysts have increased their Q3 2025 EPS estimate for BioCryst Pharmaceuticals to $0.07 per share, up from $0.04, maintaining an "Outperform" rating with a price target of $18.00.
• In its latest quarterly earnings report, BioCryst Pharmaceuticals surpassed expectations by reporting a $0.15 EPS and 49.5% revenue growth year-over-year, with total revenue of $163.35 million.
• The company has a consensus rating of "Buy" among analysts, with an average price target of $16.70, reflecting positive sentiment regarding its future performance.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Wedbush lifted their Q3 2025 earnings estimates for shares of BioCryst Pharmaceuticals in a report released on Monday, August 4th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $0.07 for the quarter, up from their prior estimate of $0.04. Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q4 2025 earnings at $0.04 EPS and FY2028 earnings at $1.05 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. During the same quarter last year, the company posted ($0.06) earnings per share. The firm's quarterly revenue was up 49.5% on a year-over-year basis.

A number of other brokerages have also commented on BCRX. JPMorgan Chase & Co. lifted their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research note on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and set a $17.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday. Royal Bank Of Canada restated an "outperform" rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded down $0.05 during midday trading on Wednesday, reaching $8.30. 1,823,000 shares of the stock were exchanged, compared to its average volume of 3,745,884. BioCryst Pharmaceuticals has a 52 week low of $6.01 and a 52 week high of $11.31. The company has a fifty day moving average price of $9.32 and a 200 day moving average price of $8.75. The stock has a market capitalization of $1.74 billion, a PE ratio of -46.11, a P/E/G ratio of 1.90 and a beta of 1.10.

Institutional Trading of BioCryst Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Alkeon Capital Management LLC increased its stake in BioCryst Pharmaceuticals by 1.7% in the first quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company's stock valued at $54,105,000 after purchasing an additional 120,199 shares in the last quarter. Geode Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals by 1.9% during the second quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company's stock worth $45,296,000 after purchasing an additional 93,973 shares during the last quarter. Millennium Management LLC grew its holdings in shares of BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after acquiring an additional 3,022,769 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of BioCryst Pharmaceuticals by 25,631.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock valued at $32,441,000 after acquiring an additional 3,606,566 shares during the last quarter. Finally, Caligan Partners LP lifted its holdings in BioCryst Pharmaceuticals by 16.0% during the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after acquiring an additional 412,347 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.